National Cancer Institute; Notice of Closed Meeting, 14466-14467 [2018-06771]
Download as PDF
14466
Federal Register / Vol. 83, No. 65 / Wednesday, April 4, 2018 / Notices
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Robert C. Unfer, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, Room 3F40, MSC 9823,
Rockville, MD 20892–9823, 240–669–5035,
unferrc@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; RFA–HL–18–023:
Stimulating Access to Research in Residency
(StARR) (R38).
Date: April 27, 2018.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Ann Marie M. Cruz, Ph.D.,
Program Management & Operations Branch,
Scientific Review Program, National
Institutes of Health, NIAID, 5601 Fishers
Lane, RM 3E71, Rockville, MD 20852, 301–
761–3100, cruza@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Robert Freund, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, 301–435–
1050, freundr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 30, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 29, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–06777 Filed 4–3–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Dated: March 30, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2018–06842 Filed 4–3–18; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections 552b(c)
(4) and 552b(c)(6), Title 5 U.S.C., as
amended. The purpose of this meeting
is to evaluate requests for preclinical
development resources for potential
new therapeutics for the treatment of
cancer. The outcome of the evaluation
will provide information to internal NCI
committees that will decide whether
NCI should support requests and make
available contract resources for
development of the potential
therapeutic to improve the treatment of
various forms of cancer. The research
proposals and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; In vitro
models of hepatoxicity.
Date: April 11, 2018.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Martha Garcia, Ph.D.,
Scientific Reviewer Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2186,
MSC 7818, Bethesda, MD 20892, 301–435–
1243, garciamc@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Feb2018
Cycle 28 NExT SEP Committee Meeting.
Date: April 25, 2018.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Wing C; 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Persons: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, MD 20817,
(301) 496–4291, mroczkoskib@mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meeting
amozie on DSK30RV082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–16–
115: Optimization of Monoclonal Antibodies
for Eliminating the HIV Reservoir.
Date: April 18, 2018.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
18:12 Apr 03, 2018
Jkt 244001
[FR Doc. 2018–06839 Filed 4–3–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Center for Scientific Review; Notice of
Closed Meeting
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
E:\FR\FM\04APN1.SGM
04APN1
Federal Register / Vol. 83, No. 65 / Wednesday, April 4, 2018 / Notices
9609 Medical Center Drive, Room 3W110,
Rockville, MD 20850, (240) 276–5683,
toby.hecht2@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 29, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Thomas F. Conway, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G51, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, 240–507–9685,
thomas.conway@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
[FR Doc. 2018–06771 Filed 4–3–18; 8:45 am]
Dated: March 30, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2018–06843 Filed 4–3–18; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
amozie on DSK30RV082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Detection of HIV for SelfTesting (R61/R33).
Date: May 1–2, 2018.
Time: 10:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Roberta Binder, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G21A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5050,
rbinder@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning Grants (R34).
Date: May 1, 2018.
Time: 1:00 p.m. to 5:00 p.m.
VerDate Sep<11>2014
18:12 Apr 03, 2018
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Omics &
Spatial Interrogation of Alzheimer’s Disease.
Date: May 8, 2018.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892.
Contact Person: Nijaguna Prasad, Ph.D.,
Scientific Review Branch, National Institute
of Aging, National Institutes of Health, Suite
2W200, Bethesda, Md 20892, 301–496–9667,
nijaguna.prasad@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
14467
Dated: March 30, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–06841 Filed 4–3–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2010–0164]
National Boating Safety Advisory
Council
U.S. Coast Guard, Department
of Homeland Security.
ACTION: Notice of Federal Advisory
Committee Meeting.
AGENCY:
The National Boating Safety
Advisory Council and its
Subcommittees will meet to discuss
issues relating to recreational boating
safety. These meetings will be open to
the public.
DATES: Meetings: The National Boating
Safety Advisory Council will meet on
Tuesday, May 8, 2018, from 12:30 p.m.
to 6:00 p.m. and on Thursday, May 10,
2018 from 8:30 a.m. to 11:30 a.m. The
Boats and Associated Equipment
Subcommittee will meet on Wednesday,
May 9, 2018, from 8:30 a.m. to 10:30
a.m. The Prevention through People
Subcommittee will meet on Wednesday,
May 9, 2018, from 10:45 a.m. to 2:15
p.m. The Recreational Boating Safety
Strategic Planning Subcommittee will
meet on Wednesday, May 9, 2018, from
2:30 p.m. to 5:00 p.m. Please note that
these meetings may conclude early if
the National Boating Safety Advisory
Council has completed all business.
Comments and supporting
documents: To ensure your comments
are received by Council members before
the meetings, submit your written
comments no later than April 30, 2018.
Written comments must be submitted
using Federal eRulemaking Portal at
https://www.regulations.gov. If you
encounter technical difficulties with
comments submission, contact the
individual listed in the FOR FURTHER
INFORMATION CONTACT section below.
ADDRESSES: All meetings will be held in
Portland, Oregon at the Broadway Room
of the Hilton Portland Downtown, 921
SW Sixth Avenue, Portland, OR 97204.
https://www3.hilton.com/en/hotels/
oregon/hilton-portland-downtownPDXPHHH/.
For information on facilities or
services for individuals with disabilities
or to request special assistance at the
SUMMARY:
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 83, Number 65 (Wednesday, April 4, 2018)]
[Notices]
[Pages 14466-14467]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-06771]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c) (4) and 552b(c)(6), Title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for the treatment of cancer. The outcome of the evaluation will provide
information to internal NCI committees that will decide whether NCI
should support requests and make available contract resources for
development of the potential therapeutic to improve the treatment of
various forms of cancer. The research proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Feb2018 Cycle 28 NExT SEP Committee Meeting.
Date: April 25, 2018.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program
Portfolio.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Wing C; 6th Floor, Conference Room 10, Bethesda, MD
20892.
Contact Persons: Barbara Mroczkowski, Ph.D., Executive
Secretary, Discovery Experimental Therapeutics Program, National
Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD
20817, (301) 496-4291, [email protected].
Toby Hecht, Ph.D., Executive Secretary, Development Experimental
Therapeutics Program, National Cancer Institute, NIH,
[[Page 14467]]
9609 Medical Center Drive, Room 3W110, Rockville, MD 20850, (240)
276-5683, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: March 29, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-06771 Filed 4-3-18; 8:45 am]
BILLING CODE 4140-01-P